HDFC Charity Fund for Cancer Cure - Dir (75% IDCW Donat - Mutual Fund Analysis | Complete Fund Review with Performance, Portfolio, and Risk Analysis
Comprehensive analysis of HDFC Charity Fund for Cancer Cure - Dir (75% IDCW Donat (44240) providing detailed insights into fund performance, portfolio holdings, risk metrics, expense ratios, and investment recommendations.
HDFC Charity Fund for Cancer Cure - Dir (75% IDCW Donation Option)
HDFC Asset Management Company Ltd
To generate income through investments in Debt / Money Market Instruments and Government Securities maturing on or before the maturity date of the Scheme. There is no assurance that the investment objective of the Scheme will be realized.
Fund Health Radar
A comprehensive at-a-glance view of key mutual fund health indicatorsHover or click any card to view detailed metrics
Performance
Moderate Returns
Risk
Moderate Risk
Expenses
Low Expense Ratio
Portfolio Mix
Debt Focused
Management
Established Team
Quality Score
Average Quality
HDFC Charity Fund for Cancer Cure - Dir (75% IDCW Donation Option) - NAV History (1Y)
Showing 1Y NAV history
Performance across different time periods
Neutral Entry Point
Fund shows mixed signals. Consider your investment timeline and risk tolerance.
Review detailed analysis and consider dollar-cost averaging through SIPs.
Neutral Entry Point
Fund shows mixed signals. Consider your investment timeline and risk tolerance.
Review detailed analysis and consider dollar-cost averaging through SIPs.
Key Factors Analysis
Cost Efficiency
Fund management costs
Alpha Generation
Outperformance vs benchmark
1-Year Returns
Recent performance momentum
Risk Assessment
Risk-adjusted returns
Long-term Track Record
Historical performance consistency
Management Stability
Fund manager experience
Fund Size
Assets under management
Equity Exposure
Market exposure level
Investment Timing Insights
See how your money can grow and compare with popular investment options
Your Investment
Compare With Popular Options
Disclaimer: Returns are illustrative and based on assumed rates. Mutual fund investments are subject to market risk. Please read scheme documents carefully.
Risk Metrics (3 Years)
Risk Level
| Company | Industry | % Assets |
|---|---|---|
| Gujarat 2026 | Govt. Securities | 52.61% |
| Andhra Pradesh 2026 | Govt. Securities | 21.06% |
| Gujarat 2026 | Govt. Securities | 15.78% |
| Maharashtra 2026 | Govt. Securities | 5.26% |
| Net CA & Others | Debt Others | 2.04% |
| Maharashtra 2026 | Govt. Securities | 1.53% |
| Tamil Nadu 2026 | Govt. Securities | 1.01% |
| TREPS | Debt Others | 0.71% |
Compare against Fixed Maturity Plans category average
Performance Summary
This comparison shows how the fund performs relative to the Fixed Maturity Plans category average. Positive values indicate outperformance, while negative values show underperformance.
Compare with similar funds in Fixed Maturity Plans category
HDFC Charity Fund for Cancer Cure - Dir (75% IDCW Donation Option) vs Category Average
Similar Funds Comparison
| Fund Name | NAV | 3M | 6M | 1Y |
|---|---|---|---|---|
| TRUSTMF FMP - Series II (1196 Days) - Dir (G) | ₹1237.99 | 1.83% | 4.65% | 8.90% |
| TRUSTMF FMP - Series II (1196 Days) - Reg (G) | ₹1234.60 | 1.81% | 4.60% | 8.80% |
| TRUSTMF FMP - Series II (1196 Days) - Reg (IDCW) | ₹1234.60 | 1.81% | 4.60% | 8.80% |
| Nippon India Interval Fund - Qrtly-Sr.II-Dir (G) | ₹37.17 | 1.45% | 3.05% | 6.54% |
| Nippon India Interval Fund-Annual-Sr.I Retail (G) | ₹36.94 | 1.97% | 3.70% | 7.29% |
| Nippon India Interval Fund - Qrtly-Sr.II (G) | ₹36.61 | 1.43% | 3.03% | 6.49% |
| UTI-Annual Interval Fund - I - Inst (G) | ₹36.30 | 1.33% | 2.98% | 6.29% |
| UTI-Annual Interval Fund - I - Direct (G) | ₹35.33 | 1.36% | 3.03% | 6.37% |
| UTI-Annual Interval Fund - I (G) | ₹34.90 | 1.33% | 2.98% | 6.26% |
| Aditya Birla SL Interval Income-Qrtly-Sr.I-Dir (G) | ₹34.66 | 1.36% | 2.93% | 6.55% |
Category Average Returns
Anil Bamboli
A seasoned investment professional with over 2 years of experience in equity research and fund management. Known for consistent performance and a disciplined investment approach focused on quality growth stocks.